185 related articles for article (PubMed ID: 36750899)
21. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
[TBL] [Abstract][Full Text] [Related]
22. Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant).
Wu JJ; Lee PH; Zheng ZR; Huang YH; Tseng JS; Hsu KH; Yang TY; Yu SL; Chen KC; Chang GC
Medicine (Baltimore); 2022 Jun; 101(24):e29381. PubMed ID: 35713442
[TBL] [Abstract][Full Text] [Related]
23. Dynamic changes in the systemic immune-inflammation index predict the prognosis of EGFR-mutant lung adenocarcinoma patients receiving brain metastasis radiotherapy.
Wang Q; Tan X; Deng G; Fu S; Li J; Li Z
BMC Pulm Med; 2022 Mar; 22(1):75. PubMed ID: 35241046
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.
Yoshida H; Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Ajimizu H; Yamazoe M; Kuninaga K; Ogimoto T; Hosoya K; Itotani R; Sakamori Y; Kim YH; Hirai T
Eur J Cancer; 2021 Feb; 144():317-325. PubMed ID: 33385948
[TBL] [Abstract][Full Text] [Related]
25. Survival of patients with KRAS G12C mutated stage IV non-small cell lung cancer with and without brain metastases treated with immune checkpoint inhibitors.
Swart EM; Noordhof AL; Damhuis RAM; Kunst PWA; De Ruysscher DKM; Hendriks LEL; van Geffen WH; Aarts MJ
Lung Cancer; 2023 Aug; 182():107290. PubMed ID: 37419045
[TBL] [Abstract][Full Text] [Related]
26. Overall survival after initial radiotherapy for brain metastases; a population based study of 2140 patients with non-small cell lung cancer.
Karlsson AT; Hjermstad MJ; Omdahl T; Aass N; Skovlund E; Hellebust TP; Johansen S; Kaasa S; Yri OE
Acta Oncol; 2021 Aug; 60(8):1054-1060. PubMed ID: 34032536
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
Zhai X; Li W; Li J; Jia W; Jing W; Tian Y; Xu S; Li Y; Zhu H; Yu J
Radiat Oncol; 2021 Dec; 16(1):233. PubMed ID: 34865626
[TBL] [Abstract][Full Text] [Related]
28. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
29. Assessment of prognostic scores of brain metastases from lung adenocarcinoma with EGFR mutations.
Li H; Lian J; Jin H; Wang W; Cao J; Zhang X; Song X; Jia S; Jia H; Ren J; Han S; Yang W; Xi Y; Lan S
J Neurooncol; 2017 May; 133(1):129-135. PubMed ID: 28391386
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for
Shiozawa T; Numata T; Tamura T; Endo T; Kaburagi T; Yamamoto Y; Yamada H; Kikuchi N; Saito K; Inagaki M; Kurishima K; Funayama Y; Miyazaki K; Koyama N; Furukawa K; Nakamura H; Kikuchi S; Ichimura H; Sato Y; Sekine I; Satoh H; Hizawa N
Anticancer Res; 2022 May; 42(5):2583-2590. PubMed ID: 35489768
[TBL] [Abstract][Full Text] [Related]
31. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
Gui Q; Liu J; Li D; Xu C
World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198
[TBL] [Abstract][Full Text] [Related]
32. Osimertinib for
Xie L; Nagpal S; Wakelee HA; Li G; Soltys SG; Neal JW
Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
[TBL] [Abstract][Full Text] [Related]
33. Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan.
Yoshida H; Kim YH; Iwatsubo S; Sakaguchi C; Sakamori Y; Nagai H; Ozasa H; Mio T; Hirai T
Oncology; 2020; 98(7):460-467. PubMed ID: 32222702
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression.
Wakuda K; Yabe M; Kodama H; Nishioka N; Miyawaki T; Miyawaki E; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Ono A; Kenmotsu H; Naito T; Murakami H; Harada H; Endo M; Gon Y; Takahashi T
Lung Cancer; 2021 Jan; 151():60-68. PubMed ID: 33246646
[TBL] [Abstract][Full Text] [Related]
35. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
[TBL] [Abstract][Full Text] [Related]
36. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
[TBL] [Abstract][Full Text] [Related]
37. Effect of brain radiotherapy strategies on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis.
Deng G; Zhang Y; Ke J; Wang Q; Qin H; Li J; Li Z
J Transl Med; 2021 Nov; 19(1):486. PubMed ID: 34847914
[TBL] [Abstract][Full Text] [Related]
38. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant.
Zhao L; Cai X; Chen D; Ye X; Gao M; Lu L; Su H; Su M; Hou M; Xie C
Radiat Oncol; 2019 Dec; 15(1):3. PubMed ID: 31892337
[TBL] [Abstract][Full Text] [Related]
40. Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis.
Li Z; Shen D; Zhang J; Zhang J; Yang F; Kong D; Kong J; Zhang A
BMC Cancer; 2019 Nov; 19(1):1104. PubMed ID: 31727054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
